Cardiac Complications After SARS-CoV-2 Infection and MRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022
Supporting Files
Public Domain
-
-
-
Series:
File Language:
English
Details
-
Description:What is already known about this topic? Studies have found an increased risk for cardiac Complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination, but few have compared these risks.
What is added by this report? Data from 40 health care systems participating in a large network found that the risk for cardiac Complications was significantly higher after SARS-CoV-2 infection than after mRNA COVID-19 vaccination for both males and females in all age groups.
What are the implications for public health practice? These findings support continued use of recommended mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
Cardiac Complications, particularly myocarditis and pericarditis, have been associated with SARS-CoV-2 (the Virus that causes COVID-19) infection (1–3) and mRNA COVID-19 vaccination (2–5). Multisystem inflammatory syndrome (MIS) is a rare but serious complication of SARS-CoV-2 infection with frequent cardiac involvement (6). Using electronic health record (EHR) data from 40 U.S. health care systems during January 1, 2021–January 31, 2022, investigators calculated incidences of cardiac outcomes (myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS) among persons aged ≥5 years who had SARS-CoV-2 infection, stratified by sex (male or female) and age group (5–11, 12–17, 18–29, and ≥30 years). Incidences of myocarditis and myocarditis or pericarditis were calculated after first, second, unspecified, or any (first, second, or unspecified) dose of mRNA COVID-19 (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) vaccines, stratified by sex and age group. Risk ratios (RR) were calculated to compare risk for cardiac outcomes after SARS-CoV-2 infection to that after mRNA COVID-19 vaccination. The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12–17 years after the second vaccine dose; however, within this demographic group, the risk for cardiac outcomes was 1.8–5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose. The risk for cardiac outcomes was likewise significantly higher after SARS-CoV-2 infection than after first, second, or unspecified dose of mRNA COVID-19 vaccination for all other groups by sex and age (RR 2.2–115.2). These findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
Suggested citation for this article: Block JP, Boehmer TK, Forrest CB, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022. MMWR Morb Mortal Wkly Rep. ePub: 1 April 2022.
mm7114e1.htm?s_cid=mm7114e1_w
mm7114e1-H.pdf -
Subjects:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Document Type:
-
Corporate as Subject:
-
Place as Subject:
-
Pages in Document:7 pdf pages
-
Volume:71
-
Download URL:
-
File Type:
-
Collection(s):
-
Main Document Checksum:urn:sha-512:a64d5056ac1169f7646359b8ebf3d8bba617309e80ac7b029704b2500a9699564ee93f68aba9d0fc18d1f9dd29985f8045ed83abad61e9d3a15aee9614ae5a4a
Supporting Files
File Language:
English
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings, journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Morbidity and Mortality Weekly Report (MMWR)